HeartFlow vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
HeartFlow creates AI-powered, non-invasive 3D models of coronary arteries from CT scans to guide treatment of coronary artery disease, with FDA clearance and coverage from major insurers including Cigna.
About
HeartFlow, Inc. is a Redwood City, California–based medical technology company founded in 2011 that applies artificial intelligence to cardiac imaging to transform the diagnosis and management of coronary artery disease (CAD). Its flagship HeartFlow FFRCT Analysis generates a personalized, color-coded 3D model of a patient's coronary arteries from a standard CT scan, calculating fractional flow reserve values non-invasively to identify which blockages actually restrict blood flow. The technology is backed by more than 600 peer-reviewed publications and has helped clinicians manage over 400,000 patients worldwide.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.